In vitro Tumor cell targeting with the folate receptor specific MR contrast agent P866
Saborowski O, Bauer J, Fu Y, Corot C, Daldrup-Link H
University of California San Francisco
The vitamin folic acid has become a useful ligand for targeted cancer imaging and therapies, because it binds to a tumor associated antigen known as the folate receptor (FR). The purpose of this in vitro study was to evaluate the specific uptake of the new FR specific MR contrast agent P866 by varying tumor cell lines. P866 showed a specific uptake in FR positive breast cancer cells. The P866 uptake resulted in a significant T1-effect for all targeted tumor cells, and this effect was significantly higher at 1.5 T compared to 3T.